Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention Analysis from the controlled abciximab and device investigation to lower late angioplasty complications (cadillac) trial by Nikolsky, Eugenia et al.
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OBJECTIVES We sought to investigate the impact of anemia in patients with acute myocardial infarction
(AMI) undergoing primary percutaneous coronary intervention (PCI).
BACKGROUND The prognostic importance of anemia on primary PCI outcomes is unknown.
METHODS In the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications
(CADILLAC) trial, 2,082 patients of any age with AMI within 12 h onset undergoing primary
PCI were randomized to balloon angioplasty versus stenting, each  abciximab. Outcomes were
stratified by the presence of anemia at baseline, as defined by World Health Organization criteria
(hematocrit 39% for men and 36% for women).
RESULTS Anemia was present in 260 (12.8%) of 2,027 randomized patients with baseline laboratory
values. Patients with versus without baseline anemia more frequently developed in-hospital
hemorrhagic complications (6.2% vs. 2.4%, p  0.002), had higher rates of blood product
transfusions (13.1% vs. 3.1%, p  0.0001), and had a prolonged (median 4.1 vs. 3.5 days, p
 0.0001) and more expensive (median costs $12,434 vs. $11,603, p  0.002) index hospital-
ization. Patients with versus without anemia had strikingly higher mortality during hospitalization
(4.6% vs. 1.1%, p 0.0003), at 30 days (5.8% vs. 1.5%, p 0.0001), and at 1 year (9.4% vs. 3.5%,
p  0.0001). The rates of disabling stroke at 30 days (0.8% vs. 0.1%, p  0.005) and at 1 year
(2.1% vs. 0.4%, p 0.0007) were also significantly higher in patients with anemia. By multivariate
analysis, anemia was an independent predictor of in-hospital mortality (hazard ratio, 3.26; p 
0.048) and one-year mortality (hazard ratio, 2.38; p  0.016).
CONCLUSIONS Anemia at baseline in patients with AMI undergoing primary PCI is common, and is strongly
associated with adverse outcomes and increased mortality. (J Am Coll Cardiol 2004;44:
547–53) © 2004 by the American College of Cardiology Foundationa
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aarly and late prognosis of patients with acute myocardial
nfarction (AMI) is principally dependent on three major
ariables: left ventricular function, susceptibility to ventric-
lar arrhythmias, and residual ischemia after reperfusion
1–3). Reduction in the hemoglobin concentration may
ompromise oxygen supply to infarcted or ischemic myo-
ardium, which may promote arrhythmias, worsen hypoten-
ion, and increase infarct size (4–6). Two prior studies in
atients with AMI treated conservatively suggest that early
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Manuscript received January 12, 2004; revised manuscript received February 24,(004, accepted March 11, 2004.nd late mortality may be increased in patients presenting
ith anemia (7,8). No data are available regarding the
mpact of anemia on outcomes of patients undergoing
rimary percutaneous coronary intervention (PCI) for AMI.
herefore, we examined the database from the large, mul-
icenter randomized Controlled Abciximab and Device
nvestigation to Lower Late Angioplasty Complications
CADILLAC) trial to determine the effect of anemia on
arly and late outcomes of patients with AMI undergoing
rimary PCI.
ETHODS
he CADILLAC protocol, inclusion and exclusion criteria,
nd principal results have been reported in detail elsewhere
9). Briefly, 2,082 patients of any age with AMI within 12 h
nset undergoing primary PCI were randomized to balloon
ngioplasty versus stenting with the Multilink stent
Guidant Corp., Santa Clara, California), each with versus
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Anemia and Primary Angioplasty Outcomes August 4, 2004:547–53ithout abciximab (Centocor, Malvern, Pennsylvania).
ith regard to hemorrhagic risk, patients were excluded
ith a history of bleeding diathesis, major surgery within
he preceding six weeks, gastrointestinal or genitourinary
leeding within six months, cerebrovascular event within
wo years, or any permanent residual neurological defect, a
istory of leukopenia, thrombocytopenia, hepatic or renal
ysfunction, or recent administration of a thrombolytic
gent. Anemia at baseline was not an exclusion criterion,
owever, and baseline laboratory values were not required to
e available before enrollment and performance of PCI.
The primary composite end point included death from
ny cause, reinfarction, repeat target vessel revascularization
TVR) as a result of ischemia, or disabling stroke after the
able 1. Baseline Clinical Characteristics and Angiographic Featu
Patients
n
linical characteristics
Male gender
Age (years) 65
Diabetes mellitus
Hypertension
Hyperlipidemia
Current smoking
Prior myocardial infarction
Prior percutaneous coronary intervention
Prior coronary bypass surgery
Prior stroke or transient ischemic attack
History of peripheral vascular disease
History of gastrointestinal bleeding
History of genitourinary bleeding
Killip class II
Body mass index (kg/m2) 26.2
Baseline hemoglobin (g/dl) 12.3
Baseline hematocrit (%) 36.0
Hematocrit range 1
Baseline platelet count (103 cells/mm3) 219
Baseline serum creatinine (mg/dl) 1.1
ST-segment elevation or left bundle branch block
Symptom onset to balloon inflation (h) 4.1
ngiographic features
Single-vessel disease
Double-vessel disease
Triple-vessel disease
Left ventricle ejection fraction (%) 50
Infarct related artery
Left anterior descending artery
Left circumflex artery
Right coronary artery
Abbreviations and Acronyms
AMI  acute myocardial infarction
CADILLAC  Controlled Abciximab and Device
Investigation to Lower Late Angioplasty
Complications trial
PCI  percutaneous coronary intervention
TIMI  Thrombolysis In Myocardial Infarction
TVR  target vessel revascularization
WHO  World Health Organizationndex procedure. The definitions of the primary end point
ave been previously described (9). Anemia was defined
sing World Health Organization (WHO) criteria as a
ematocrit value at initial presentation 39% for men and
36% for women (10).
Clinical follow-up at 30 days, 6 months, and 1 year were
erformed in all patients. All events were adjudicated by an
ndependent clinical events committee. Medical care costs
ere assessed for all U.S. patients using previously validated
ethodology (11). Detailed resource utilization data were
ecorded for all revascularization procedures, and procedural
osts were based on measured resource utilization and 2001
nit costs. Nonprocedural hospital costs were estimated by
onverting hospital charges to costs according to hospital
nd cost-center specific cost-to-charge ratios. Costs for
npatient and outpatient physician services were calculated
sing the 2001 Massachusetts Medicare fee schedule.
tatistical analysis. Categorical variables were compared
ith the Fisher exact test. Continuous variables are pre-
ented as medians with interquartile ranges, and were
ompared using the Kruskal-Wallis test. Survival data was
stimated by the Kaplan-Meier method and compared by
he log-rank test. Multivariate analysis of predictors of
eath at several time periods was performed using Cox
h Anemia
60
Patients Without Anemia
n  1,767 p Value
73.9% 0.05
4) 58 (50, 68)  0.0001
15.8% 0.03
46.7% 0.003
37.9% 0.68
45.2%  0.0001
13.8% 0.85
10.9% 0.21
2.0% 0.99
2.9% 0.56
2.2% 0.02
0.9% 0.02
0.2%  0.99
10.0% 0.0009
, 29.7) 27.4 (24.9, 30.6) 0.0005
, 13.0) 14.9 (14.0, 15.7)  0.0001
, 38.2) 43.7 (41.1, 46.2)  0.0001
8.9 36.0–66.8 —
276) 232 (195, 273) 0.06
1.4) 1.0 (0.9, 1.2)  0.0001
87.5% 0.39
6.0) 4.0 (2.9, 6.1) 0.40
51.7% 0.21
32.5% 0.14
15.8% 0.93
0) 50 (40, 55) 0.46
37.5% 0.34
18.3% 0.12
44.1% 0.03res
Wit
 2
68.1%
(56, 7
21.5%
56.5%
39.2%
29.2%
13.1%
13.5%
1.9%
3.5%
5.0%
2.7%
0%
17.4%
(23.8
(11.5
(34.1
2.7–3
(178,
(0.9,
89.7%
(3.1,
47.3%
37.3%
15.4%
(40, 6
34.2%
14.2%
51.5%
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August 4, 2004:547–53 Anemia and Primary Angioplasty Outcomesroportional hazards regression with stepwise selection
sing entry and exit criteria of p  0.1. The candidate
ariables entered in the model included age, gender, diabe-
es mellitus, hypertension, hypercholesterolemia, current
moking, history of prior myocardial infarction or coronary
rtery bypass graft surgery, Killip class 2 creatinine clear-
nce, left anterior descending artery as an infarct vessel,
riple-vessel disease, treatment with abciximab or stent, time
rom the symptom onset to the first balloon inflation, and
aseline anemia (as a binary variable) or baseline hematocrit
as a continuous variable). Separate models were then
enerated adding in baseline medication use. All analyses
ere two-sided, and significance was established at the 0.05
evel.
ESULTS
aseline clinical characteristics. A baseline hematocrit
efore PCI was available in 2,027 (97.4%) of the 2,082
atients enrolled in the CADILLAC trial, 260 (12.8%) of
hom had anemia. As seen in Table 1, patients with anemia
ere older, more frequently female, and had smaller body
ass index. Pre-existing diabetes mellitus, hypertension,
eripheral arterial disease, and past gastrointestinal bleeding
ere all significantly more common in patients with anemia.
ongestive heart failure at the time of presentation was also
Table 2. Procedural Results
Patients With
n  2
TIMI flow
Baseline
Grade 0 or 1 67.9%
Grade 2 9.1%
Grade 3 23.0%
Final
Grade 0 or 1 2.0%
Grade 2 3.2%
Grade 3 94.8%
Reference diameter (mm)
Baseline 2.93 (2.60
Final 2.94 (2.66
Minimal luminal diameter (mm)
Baseline 0 (0, 0
Final 2.47 (2.10
Diameter stenosis (%)
Baseline 100 (73.4
Final 17.4 (9.1,
Procedural success 89.2%
Stent implanted
Per randomization 48.8%
As bail-out for complications 6.5%
Abciximab administered
Per randomization 55.0%
As bail-out for complications 4.6%
TIMI  Thrombolysis In Myocardial Infarction.ore frequent in anemic patients. procedural and in-hospital results. Pre- and post-PCI
umen dimensions, procedural success rates, and final
hrombolysis In Myocardial Infarction (TIMI) flow grades
ere similar in patients with and without anemia (Table 2),
s were peak creatine phosphokinase levels (median 1,339
s. 1,413 U/l, respectively, p  0.13). Patients with versus
ithout anemia more frequently developed moderate or
evere hemorrhagic complications in-hospital (6.2% vs.
.4%, p  0.002), and had higher rates of blood product
ransfusions (13.1% vs. 3.1%, respectively, p  0.0001).
artly as a result, the index hospitalization was significantly
rolonged in patients with anemia (4.1 [3.0, 6.5] vs. 3.5
2.8, 5.1] days, p  0.0001), and in-hospital costs were
ignificantly greater ($12,434 [$10,158, $16,412] vs.
11,603 [$9,587, $14,631], p  0.002).
linical follow-up. As seen in Table 3 and Figure 1, rates
f mortality (all-cause, cardiac, and noncardiac) and dis-
bling stroke were markedly higher in patients with baseline
nemia compared with those without anemia, during the
n-hospital phase and at 30 days and 1 year. Mortality was
lso higher in patients with baseline anemia between the
ime of discharge and one year (6.2% vs. 2.4%, p  0.001).
n patients with anemia, the majority of disabling strokes at
ne year were ischemic (1.7%), and the minority (0.1%)
ere hemorrhagic. In patients without anemia, stroke was
emorrhagic in 0.1% of patients, ischemic in 0.1% of
mia Patients Without Anemia
n  1,767 p Value
68.0% 0.99
10.0% 0.74
22.0% 0.75
1.3% 0.39
3.0% 0.84
95.6% 0.51
) 2.95 (2.61, 3.33) 0.31
) 2.99 (2.63, 3.37) 0.31
0 (0, 0.72) 0.80
) 2.46 (2.09, 2.81) 0.58
) 100 (75.5, 100) 0.69
18.1 (8.9, 27.1) 0.83
91.6% 0.22
49.9% 0.79
8.4% 0.33
49.7% 0.11
2.8% 0.12Ane
60
, 3.26
, 3.28
.78)
, 2.74
, 100
26.4)atients, and unclassified in 0.1% of patients.
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Anemia and Primary Angioplasty Outcomes August 4, 2004:547–53Mortality was significantly increased in both men and
omen with anemia (Fig. 2A); the increase in disabling
troke with anemia was significant in women, and a similar
rend was present in men (Fig. 2B). There were no
ifferences in the rates of reinfarction or recurrent ischemia
ecessitating repeat TVR between anemic and nonanemic
atients.
ultivariate analysis. Considering baseline clinical and
ngiographic variables, anemia was identified as an inde-
endent predictor of in-hospital and one-year mortality by
ultivariate analysis (Table 4). Similarly, when baseline
ematocrit as a continuous variable rather than anemia was
ntroduced into the regression model, hematocrit was also a
ignificant predictor of one-year mortality (hazard ratio 
.06 [95% confidence interval 1.01 to 1.12], p  0.042).
hen added to these models, neither nadir hematocrit
alue, absolute decrease in hematocrit, or blood transfusions
orrelated with mortality. There was no statistically signif-
cant interaction between baseline hematocrit and other
ariables (age, gender, prior myocardial infarction, prior
oronary bypass surgery, hypertension, diabetes, hypercho-
esterolemia, smoking, peripheral vascular disease, conges-
ive heart failure, and creatinine clearance) when specifically
ssessed with an interaction term in either in-hospital or in
ne-year multivariable models.
edication use. At admission, patients with anemia were
Table 3. In-Hospital, 30-Day, and 1-Year Ou
Patients W
Anemi
n  26
All-cause mortality
In-hospital 4.6%
30-day 5.8%
1-year 10.2%
Cardiac mortality
In-hospital 2.4%
30-day 2.8%
1-year 6.1%
Noncardiac mortality
In-hospital 2.3%
30-day 3.2%
1-year 4.2%
Disabling stroke
In-hospital 0.4%
30-day 0.8%
1-year 2.1%
Reinfarction
In-hospital 0.8%
30-day 1.6%
1-year 2.9%
Target vessel revascularization
In-hospital 2.7%
30-day 3.5%
1-year 14.2%
Composite adverse events
In-hospital 7.7%
30-day 10.4%
1-year 20.3%ess likely to be treated with aspirin than those without pnemia. At discharge, 30-day, and 1-year follow-up, signif-
cantly fewer patients with baseline anemia were treated
ith aspirin, beta-blockers, and statins (Table 5). While
ore patients with anemia were prescribed angiotensin-
onverting enzyme inhibitors or receptor blockers at dis-
harge, use of this class of drugs was similar in patients with
nd without anemia at 30 days and 1 year. When admission
edication use was added to the multivariate models,
aseline anemia continued to be an independent predictor
f mortality during both the in-hospital period (hazard ratio
3.36 [95% confidence interval 1.10 to 11.20], p  0.05)
nd at 1 year (hazard ratio  2.38 [95% confidence interval
.18 to 14.80], p  0.016).
ISCUSSION
rior studies have suggested a link between baseline hematocrit
nd adverse outcomes in patients with cardiac disease and
MI treated conservatively. In a retrospective analysis of
8,974 Medicare beneficiaries, lower baseline hematocrit val-
es were associated with higher 30-day mortality rates after
MI; only 10% of patients were treated by PCI in this series,
owever (7). Similarly, one-year mortality was higher in
nemic patients in a report from the Myocardial Infarction
ata Acquisition System (8). The association between baseline
ematocrit and outcomes after primary PCI have not been
es Stratified by Baseline Anemia
Patients Without
Anemia
n  1,767 p Value
1.1% 0.0003
1.5%  0.0001
3.5%  0.0001
1.0% 0.06
1.4% 0.02
2.5% 0.002
0.2% 0.001
0.3%  0.0001
1.1% 0.0002
0.0% 0.12
0.1% 0.005
0.4% 0.0007
0.2% 0.12
0.7% 0.16
2.3% 0.58
2.4% 0.83
3.8% 0.85
16.7% 0.34
3.6% 0.004
5.2% 0.0008
17.3% 0.15tcom
ith
a
0reviously examined.
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August 4, 2004:547–53 Anemia and Primary Angioplasty OutcomesIn the present large trial of contemporary mechanical
eperfusion strategies in AMI, anemia, as defined by WHO
riteria, was common, occurring in 12.8% of patients. As
atients with hemorrhagic diatheses and recent bleeding
ere excluded from the CADILLAC trial, the true inci-
ence of anemia in a more general population of patients
resenting for primary PCI is likely to be higher, especially
iven the increasing incidence of anemia as the population
ges (7,12,13). Patients with anemia had an increased
requency of comorbid risk factors known to worsen prog-
osis after AMI, including advanced age, female gender,
nd diabetes mellitus (14,15). Despite similar rates of
rocedural success and infarct size, patients with baseline
nemia had a significantly more complicated hospital
ourse, including greater rates of hemorrhagic complications
nd blood product transfusion requirements. Hospitaliza-
ion was significantly prolonged in patients with anemia,
nd costs were significantly greater. Most importantly,
aseline anemia was strongly associated with an approxi-
ate three-fold increase in in-hospital, 30-day, and 1-year
ortality. The impact of anemia on early and late death was
resent in both genders (though was especially profound in
omen), despite the different gender-based thresholds for
nemia as established by WHO (10). Anemia was also
trongly associated with an increased risk of disabling
troke, especially in women, a finding not previously re-
orted.
The reasons for the worse outcomes in anemic patients
ith AMI treated with primary PCI are likely multifacto-
ial. Anemia may by itself confer excess risk; decreased
lood oxygen levels may be arrhythmogenic, directly exac-
rbate myocardial ischemia, activate the sympathetic ner-
Figure 1. Cumulative risk of deathous system, and result in cerebral hypoperfusion (4–6). plternatively, anemia was a covariate with other high-risk
eatures known to reduce survival after AMI. Patients with
nemia were older, more commonly women, and had a
igher prevalence of cardiovascular risk factors including
iabetes and chronic renal insufficiency, factors known to
orsen the prognosis of patients after AMI and primary
CI (14–19). Peripheral arterial disease, which is a marker
f diffuse atherosclerosis (20,21), was more prevalent in
atients with anemia. Clinical congestive heart failure was
lso significantly more common at presentation in patients
ith anemia, although left ventricular ejection fraction was
ot measured to be different. Even after multivariate adjust-
ent for the important confounders, anemia remained an
ndependent predictor of in-hospital and one-year mortal-
ty. However, multivariate models cannot entirely account
or the baseline differences, and adjusted effects may still be
nfluenced by residual confounding. Additional clinical
easurements not included in this analysis (e.g., certain
omorbidities or inflammatory markers) may also interact
ith anemia.
Differences in pharmacologic treatment may also have
ontributed to the worse late prognosis in patients with
nemia. Specifically, anemic patients were less likely to be
reated with aspirin, beta-blockers, and statins, all of which
re known to prolong survival after AMI (22–25). When
ifferences in medication use at the time of admission were
onsidered in the multivariate model, aspirin continued to
e an independent determinate of mortality both in-hospital
nd at one year. These models are unable to correct for
ostdischarge medication use, however, as approximately
ne-half of the deaths in patients with anemia occurred
efore hospital discharge. Notably, almost one-fifth of
tients with versus without anemia.in paatients with anemia (18.8%) were not receiving aspirin at
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Anemia and Primary Angioplasty Outcomes August 4, 2004:547–53ne-year follow-up, presumably due to their increased
ncidence of preadmission gastrointestinal bleeding, their
reater rate of hemorrhagic events during the index hospi-
alization, and possible concerns about recurrent bleeding.
onsidering the impact of anemia on late survival in
ospital survivors, the decreased mortality between the time
f discharge and one year in patients with a reduced baseline
ematocrit may be, at least partly, explained by the lower
ate of aspirin prescription at discharge. Of note, prior
tudies demonstrating increased late mortality in patients
igure 2. Rates of survival (A) and disabling stroke (B) at 1 year in patients
ndergoing percutaneous coronary intervention for acute myocardial in-
arction stratified by baseline anemia and gender. Open bars  30 days;
olid bars  1 year.
Table 4. Multivariate Predictors of Mortality
In-hospital mortality
Ejection fraction (lower)
Creatinine clearance (lower)
Baseline anemia
1-year mortality
Ejection fraction (lower)
Age (older)
Left anterior descending infarct artery
Triple-vessel disease
Baseline anemia
Female genderith anemia and cardiovascular disorders did not examine
he extent to which differences in medication usage may
ave contributed to the worse prognosis with this condition
8,26).
tudy limitations. This post-hoc analysis was not pre-
pecified and should, thus, be considered hypothesis-
enerating, and complementary to large, prospectively col-
ected observational databases. The causes of anemia in the
atients in our study were not known, and the prognostic
mportance of anemia may vary with different etiologies.
he indications for and timing of blood product transfu-
ions were not protocol-specified but, rather, left to local
tandards of care; whether a policy of early routine blood
ransfusion in anemic patients would improve their prog-
Hazard Ratio
5% Confidence Interval) p Value
1.10 (1.05, 1.15)  0.0001
1.03 (1.01, 1.06) 0.02
3.26 (1.01, 10.52) 0.048
1.05 (1.03, 1.09)  0.0001
1.05 (1.02, 1.08) 0.0004
2.60 (1.32, 5.09) 0.006
2.27 (1.20, 4.30) 0.01
2.38 (1.18, 4.81) 0.016
1.89 (1.02, 3.50) 0.04
able 5. Medication Use at Different Time Intervals as a
unction of Baseline Anemia
Patients
With
Anemia
n  260
Patients
Without
Anemia
n  1,767 p Value
t admission
Aspirin 33.1% 26.1% 0.02
Thienopyridine 3.1% 2.5% 0.53
ACE inhibitor or ARB 12.7% 9.0% 0.07
Beta-blocker 17.3% 14.4% 0.22
Statin 13.1% 11.8% 0.53
t discharge
Aspirin 91.2% 96.0% 0.001
Thienopyridine 65.0% 66.7% 0.57
ACE inhibitor or ARB 41.2% 33.3% 0.01
Beta-blocker 67.7% 79.2%  0.0001
Statin 20.8% 30.5% 0.001
t 30 days
Aspirin 88.5% 93.3% 0.01
Thienopyridine 52.7% 55.5% 0.38
ACE inhibitor or ARB 31.9% 31.9% 0.99
Beta-blocker 69.6% 82.1%  0.0001
Statin 29.2% 40.7% 0.0004
t 1 year
Aspirin 81.2% 87.5% 0.006
Thienopyridine 6.1% 5.9% 0.89
ACE inhibitor or ARB 30.8% 29.7% 0.71
Beta-blocker 62.3% 72.6% 0.0009
Statin 39.2% 48.7% 0.004
CE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker.(9
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August 4, 2004:547–53 Anemia and Primary Angioplasty Outcomesosis is unknown. Finally, no information was available
egarding the correction of anemia at follow-up, or whether
dditional hemorrhagic events occurred.
onclusions and clinical implications. Baseline anemia
n patients with AMI undergoing primary PCI should be
ecognized as an important risk factor for prolonged hospi-
alization, increased hospital costs, and adverse short-term
nd late outcomes, including death and disabling stroke.
edications known to improve survival in AMI patients,
ncluding enteric-coated aspirin, beta-blockers, and statins
hould not be withheld from this high-risk population if at
ll possible. Further study is warranted to determine
hether early red blood cell transfusions would improve the
rognosis of patients with anemia and AMI undergoing
rimary PCI.
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